MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1547 participants.

Also called NCT01154036

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,547 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01154036
Other papers using this trial's data
  • Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia The American journal of cardiology, 2013-12-15 DOI, PubMed 24063830
  • Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey Lipids in health and disease, 2015-05-19 DOI, PubMed 25985907, PMC4457981 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01154036. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2014-02-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Condition
Hypercholesterolemia
Intervention (Drug)
ezetimibe 10 mg
Intervention (Drug)
atorvastatin
Intervention (Drug)
Comparator: rosuvastatin
Lead sponsor
Organon and Co (class: industry)

Record details

Record id
cardio:ct-nct01154036
Content hash
52a87758bccc2713612cb00a9198874d22479174f0a49ab429ba5925a4d4e6f5